Fast-Tracking FIH to PoC Strategies for Accelerated Drug Development

Advancing novel molecules through first-in-human (FIH) studies to efficiently achieve proof of concept (PoC) is at the heart of this effort.

Early-phase drug development requires a successful balance of prudent spending and data-informed decision-making, combined with adherence to aggressive timelines and strict regulatory compliance.

Learn more about how  pharmaceutical industry experts Dr. Andreas Reichl and Dr. Kevin Schaab of Quotient Sciences emphasized the application of proven strategies across key areas to make the most of early development activities.